Composition vial contains Kanamycin acid sulfate equivalent to kanamycin base 1 gram.
Initial therapy for serious infections caused by bacterial susceptible to kanamycin. Treatment of bacterial infections of the gastrointestinal tract. Treatment of urinary tract infections caused by Proteus vulgaris, Escherichia coli, Staphylococcus spp., and Neisseria gonorrhoeae (gonorrhea). Treatment of respiratory tract and intrathoracic infections caused by Staphylococcus spp., Streptococcus pneumoniae, and Haemophilus influenzae. Relief of inflammation of the skin or localized bacterial infections, including inflammatory conditions of the ear, nose, and eyes.
DOSAGE: Adult: 0.5-1.5 g daily in 2 divided doses every 12 hours.
Paediatric: Newborn to 1 year old 7.5 mg/kg 2 times a day. Children >1 yr to 12 yrs 3-7.5 mg/kg 2 times a day.
Renal Impairment: Dosage adjustment needed.
Reconstitution: Add 1 gram of 3 mL of Sterile water for injection.
For Intramuscular use.
Hypersensitivity to kanamycin and other aminoglycosides.
Because of ototoxicity, deafness may occur. Because of nephrotoxicity, it should be used with care and reduced dosage in impaired renal function patients and children. If skin rash or the cold-like reactions occur, discontinue the drug and immediately consult the physician. If the reaction of fever, skin rash, swollen nodes, peeling of skin and mucocutaneous manifestations in mouth, throat, nose, genitourinary and eyes occur, discontinue use and consult the physician because it may be Stevens-Johnson Syndrome (SJS).
Use in Pregnancy & Lactation: Should not be used in
pregnant women.
Use in Children: Should be used with care and reduced dosage in children.
Pregnancy Category (US FDA): D.
Caution in pregnancy & lactation.
Ototoxicity, nephrotoxicity, skin rash, drug fever.
J01GB04 - kanamycin ; Belongs to the class of other aminoglycosides. Used in the systemic treatment of infections.
Kanamycin Sulfate Injection T P powd for soln for inj 1 g
1's